Overview of myelodysplastic syndromes

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Myelodysplastic syndromes (MDS) were first recognized in 1982.
• Classification systems for MDS have been revised by the French-American-British (FAB) group and the World Health Organization (WHO).
• Prognostic scoring systems, including the International Prognostic Scoring System (IPSS) and WHO Prognostic Scoring System (WPSS), are crucial for patient management.

Purpose of the Study:

• To review the evolution of MDS classification and prognostic systems.
• To highlight the role of cytogenetics in proving clonality and stratifying MDS risk.
• To discuss the impact of comorbidities, age, and molecular markers on MDS diagnosis and prognosis.

Main Methods:

• Review of historical classifications and prognostic scoring systems for MDS.
• Analysis of cytogenetic findings in MDS patient stratification.
• Examination of recent research on comorbidities, age, and molecular markers in MDS.

Main Results:

• MDS classification has advanced significantly, with WHO systems now widely adopted.
• Cytogenetics confirms clonality in most MDS cases and aids risk assessment.
• Comorbidities, patient age, and molecular markers are increasingly important for predicting MDS outcomes.

Conclusions:

• The understanding and management of MDS have progressed through improved classification and prognostic tools.
• Integrated approaches considering cytogenetics, comorbidities, age, and molecular data enhance MDS patient evaluation.
• Future research directions focus on leveraging these factors for personalized MDS treatment strategies.